Geoffrey von Maltzahn, IndigoAg

Geoffrey von Maltzahn, Co-Founder and Chief Innovation Officer IndigoAg.
IndigoAg
Geoffrey von Maltzahn, Co-Founder and Chief Innovation Officer IndigoAg.

Geoffrey is co-founder and Chief Innovation Officer for Indigo, as well as a Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in nutrition, environmental sustainability, and medicine. He is also a co-founder of Seres Therapeutics, Kaleido Biosciences, Sienna Biopharmaceuticals, Axcella Health, and others.

Geoffrey previously served as Chief Executive Officer of Kaleido Biosciences and Chief Technology Officer at Seres Therapeutics, where he led the build-out of their human microbiome R&D platforms and the discovery of SER-109, the first clinically-validated Microbiome Therapeutic. He was also VP of Product Discovery at Axcella, where he led the discovery of two clinically-validated drug candidates.

Geoffrey has been recognized with numerous patent grants, awards, and publications. He is an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed publications. Geoffrey has received a number of awards and honors, including: Business Insider's 30 Biotech Leaders Under 40, the prestigious Lemelson-MIT Student Prize, awarded to the most innovative student at MIT, and the National Inventors Hall of Fame Graduate Student Prize. He was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.